Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation

Expert Review of Cardiovascular Therapy
Gonzalo Barón-EsquiviasMarcelo Sanmartín Fernández

Abstract

Rivaroxaban is a once-daily oral anticoagulant currently marketed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This indication is largely based on the results of the ROCKET-AF trial. Although these results are robust, studies performed in clinical practice are necessary to confirm these data in real-life patients. These studies have shown rates of stroke and bleeding similar to that found in ROCKET-AF. As an anticoagulant, attention should be paid to making a correct prescription of rivaroxaban, particularly in fragile patients, to reduce the risk of bleeding. In addition, a number of studies have shown that rivaroxaban is cost-effective in clinical practice. Moreover, rivaroxaban is a good alternative to warfarin in patients undergoing elective cardioversion or atrial fibrillation ablation.

References

Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
Jun 22, 2000·The New England Journal of Medicine·J ConcatoR I Horwitz
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Sep 12, 2003·The New England Journal of Medicine·Elaine M HylekDaniel E Singer
Jan 11, 2007·Archives of Internal Medicine·Philippe Gabriel StegUNKNOWN GRACE Investigators
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Nov 8, 2011·Revista Española De Cardiología·Vivencio BarriosUNKNOWN Primary Care Group in the Clinical Cardiology Section of the Spanish Society of Cardiology
Jan 25, 2012·Circulation. Arrhythmia and Electrophysiology·Pasquale SantangeliAndrea Natale
Jun 6, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Masatsugu HoriUNKNOWN J-ROCKET AF study investigators
Feb 15, 2013·Expert Review of Cardiovascular Therapy·Vivencio Barrios, Carlos Escobar
Mar 19, 2013·Journal of the American College of Cardiology·Jonathan P PicciniUNKNOWN ROCKET AF Steering Committee & Investigators
Mar 26, 2013·Journal of the American Heart Association·Daniel E SingerUNKNOWN ROCKET AF Investigators
May 25, 2013·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Charlotte EitelGerhard Hindricks
Jul 16, 2013·Current Opinion in Hematology·Shari Ghanny, Mark Crowther
Sep 17, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·Pilar GallegoGregory Y H Lip
Oct 9, 2013·Current Opinion in Gastroenterology·Neena S Abraham, Diana L Castillo
Nov 14, 2013·Current Clinical Pharmacology·Reinhold Kreutz
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Dec 3, 2013·Journal of Thrombosis and Thrombolysis·Reinhold Kreutz
Dec 10, 2013·The Oncologist·Nicholas J Short, Jean M Connors
Dec 11, 2013·Frontiers in Pharmacology·Dagmar KubitzaScott D Berkowitz
Feb 12, 2014·Cost Effectiveness and Resource Allocation : C/E·Georgia KourlabaPanos Vardas
Feb 20, 2014·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Rui ProvidênciaSerge Boveda
Mar 20, 2014·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Gevorg StepanyanEdward P Gerstenfeld
Mar 22, 2014·Current Medical Research and Opinion·François LalibertéPatrick Lefebvre

❮ Previous
Next ❯

Citations

Sep 22, 2015·Journal of Comparative Effectiveness Research·Vivencio Barrios, José Luis Górriz
Dec 8, 2016·Expert Opinion on Pharmacotherapy·Francisco MarínMarcelo Sanmartín
Aug 25, 2016·Therapeutic Advances in Cardiovascular Disease·Rohan Shah, Manesh R Patel
Mar 21, 2017·Expert Review of Cardiovascular Therapy·Gonzalo Barón-EsquiviasMarcelo Sanmartín Fernandez
Sep 15, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Marcelo Sanmartín-Fernández, Domingo Marzal-Martín
Mar 30, 2018·Therapeutic Advances in Drug Safety·Heather L Forbes, Thomas M Polasek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.